However, recognising the utility and availability of molecular SPECT/γ-scintigraphy infrastructure, in recent years, several new 99mTc-labelled peptides have been clinically evaluated for receptor-targeted molecular imaging of the prostate-specific membrane antigen (PSMA) overexpressed in prostate cancer. The gene discussed is FOLH1; the disease is prostate carcinoma.